Phase II trial of oral fluoropirimidine rechallenge in breast cancer patients pretreated with oral fluoropirimidine agents

Phase II trial of oral fluoropirimidine rechallenge in breast cancer patients pretreated with oral fluoropirimidine agents - Fluoropirimidine rechallenge trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001528

Enrollment

Registered

2008-12-01

Start date

2007-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

Oral fluoropirimidine agents

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Advanced, metastatic or recurrent breast cancer 2) Pretreated with oral fluoropirimidine agent 3) At leaset one target lesion by RECIST 4) Progressive disease in prior treatment

Exclusion criteria

Exclusion criteria: 1) Patient who should not receive oral fluoropirimidine agent

Design outcomes

Primary

Measure	Time frame
Response rate	—

Countries

Japan

Contacts

Public ContactMasashi Ando

National cancer center hospital Breast and Medical Oncology

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026